Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary, Sapu Nano, will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation, scheduled for 2026, will highlight findings on tissue concentration–driven effects and organ-specific outcomes that go beyond traditional plasma pharmacokinetics. The research underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
Everolimus is an mTOR inhibitor used in oncology and immunosuppression, but its clinical utility is limited by systemic toxicity. Standard pharmacokinetic assessments rely on plasma drug levels, but Sapu Nano's data suggest that tissue concentrations are more predictive of adverse effects. By analyzing drug accumulation in organs such as the liver, kidney, and lungs, the researchers identified patterns that could inform safer dosing regimens. The findings are expected to guide the design of nanoparticle delivery systems that enhance drug localization to tumors while sparing healthy tissues.
“This work highlights the critical role of tissue pharmacokinetics in understanding drug safety,” said a spokesperson for Sapu Nano. “By moving beyond plasma measurements, we can better predict and mitigate toxicities, ultimately improving therapeutic outcomes.” The presentation will include comparative data on everolimus administered via conventional oral routes versus novel intravenous nanoparticle formulations.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. The company’s platform aims to address key challenges in cancer treatment, including poor drug solubility, non-specific distribution, and resistance mechanisms.
Oncotelic Therapeutics (f/k/a Mateon Therapeutics, Inc.) was formed in 1988 as OXiGENE, Inc., and changed its name to Oncotelic Therapeutics in November 2020. The company is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients, with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia through OXi 4503. The company also acquired PointR Data Inc. in November 2019 to build an AI-driven biotechnology company, and AL-101 for intranasal delivery of apomorphine to treat Parkinson’s disease and other conditions.
For more information on Oncotelic and Sapu Nano, refer to the company’s filings and the full press release at https://ibn.fm/kZzE3. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
